A new drug is effective in preventing new basal cell carcinomas in patients with an inherited predisposition to the disease.
These patients with basal cell nevus syndrome develop large numbers of basal cells, which can become locally invasive or metastatic, according to a discussion presented by renowned oncologist Dr. Daniel D. Von Hoff at the 102nd annual meeting of the American Association for Cancer Research (AACR).
In an initial study, Dr. Von Hoff and his team at TGen Clinical Research Service at Scottsdale Healthcare (TCRS) found that the drug, vismodegib (GDC-0449), a hedgehog pathway inhibitor, was effective in shrinking advanced invasive or metastatic basal cell carcinomas. TCRS was the first to evaluate vismodegib, produced by Genentech. TCRS is a partnership of the Translational Genomics Research Institute (TGen) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare in Scottsdale, Ariz.
At Sunday's conference plenary session, titled: "The Future of Cancer Research: Challenges and Opportunities," Dr. Von Hoff discussed a new prevention and treatment approach for patients who have basal cell nevus syndrome. Specifically, he discussed the effect of the drug on basal cell nevus syndrome, an advanced form of basal cell carcinoma that produces often-disfiguring tumors of the jaw, the sole of the foot, the brain and ribs.
A team of investigators from Children's Hospital Oakland Research Institute (CHORI) in Oakland, Calif., headed by Dr. Ervin H. Epstein Jr., presented dramatic results at the conference demonstrating that vismodegib entirely prevented the development of basal cell carcinomas in patients with basal cell nevus syndrome.
These findings are "a stunning result, which brings hope to patients who otherwise may need disfiguring surgery, especially for cancers that arise on the face and upper part of the body," said Dr. Von Hoff, a past president of AACR.
"We are so pleased that the results obtained by TCRS could be a part of the work that has made a difference for so many patients," said Dr. Von Hoff, who also is Physician-In-Chief and Distinguished Professor at TGen; Chief Scientific Officer at Scottsdale Healthcare and US Oncology; and Professor of Medicine at Mayo Clinic.
Basal cell nevus syndrome is an inherited genetic disease, which results in the development of multiple, sometimes hundreds of basal cell carcinomas. The sporadic (non-inherited) form of basal cell carcinoma is the most common skin cancer. While most cases are curable, in some patients there is a tendency for recurrent cancers and surgery may not be possible.
More than 15,000 physicians and researchers from across the globe attend the annual AACR conference, which runs April 2-6 at the Orange County Convention Center in Orlando, FL.
About the Virginia G. Piper Cancer Center at Scottsdale Healthcare
The Virginia G. Piper Cancer Center at Scottsdale Healthcare offers diagnosis, treatment, research, prevention and support in its facilities at the Scottsdale Healthcare Shea Medical Center, attracting patients from across Arizona and the U.S. Groundbreaking cancer research is conducted through its Scottsdale Healthcare Research Institute in collaboration with TGen and leading universities. Scottsdale Healthcare is the not-for-profit parent organization of the Scottsdale Healthcare Shea Medical Center, Scottsdale Healthcare Osborn Medical Center and Scottsdale Healthcare Thompson Peak Hospital, Virginia G. Piper Cancer Center, Scottsdale Healthcare Research Institute and Scottsdale Healthcare Foundation. For additional information, please visit www.shc.org.Press Contact:
Steve Yozwiak | EurekAlert!
Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover
First transcription atlas of all wheat genes expands prospects for research and cultivation
17.08.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Physics and Astronomy
17.08.2018 | Information Technology
17.08.2018 | Life Sciences